Summit Wealth Group LLC Co. Reduces Stock Holdings in Abbott Laboratories $ABT

Summit Wealth Group LLC Co. decreased its stake in Abbott Laboratories (NYSE:ABT) by 91.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,028 shares of the healthcare product maker’s stock after selling 21,449 shares during the period. Summit Wealth Group LLC Co.’s holdings in Abbott Laboratories were worth $254,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ABT. Invesco Ltd. boosted its holdings in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. Ninety One UK Ltd purchased a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $336,815,000. Vanguard Group Inc. boosted its holdings in Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. Alliancebernstein L.P. boosted its holdings in Abbott Laboratories by 51.0% during the 3rd quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock valued at $740,140,000 after acquiring an additional 1,865,250 shares during the period. Finally, Capital International Investors boosted its holdings in Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ABT. Citigroup dropped their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. TD Cowen dropped their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Stifel Nicolaus dropped their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. dropped their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, Sanford C. Bernstein dropped their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $119.43.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $84.80 on Friday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The stock has a market capitalization of $147.70 billion, a price-to-earnings ratio of 23.75, a P/E/G ratio of 1.40 and a beta of 0.65. The stock has a fifty day simple moving average of $99.59 and a two-hundred day simple moving average of $113.55. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the business earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Insiders Place Their Bets

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TipRanks highlighted Abbott as one of three “Strong Buy” Dividend Aristocrat stocks, which can support the stock’s appeal for income-focused investors despite a high payout ratio. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
• Neutral Sentiment: Jim Cramer called Abbott one of the “greatest American companies” while comparing the selloff to the 1999 market backdrop, a comment that may help sentiment but does not change fundamentals. Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
• Neutral Sentiment: Recent insider-trading coverage noted buying activity around Abbott, which can be viewed as a modest confidence signal but is not necessarily a major catalyst on its own. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Negative Sentiment: Investor concerns remain centered on Abbott’s post-earnings weakness, with commentary pointing to Exact Sciences dilution, legal risks, and softer Diagnostics trends as reasons the shares have been pressured. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.